Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2223572 | 1.00 | PTPN1 (0.33) | PTPN1CAMK2AGPR84FFAR1FFAR4 | |
| SCHEMBL5148636 | 1.00 | PTPN1 (0.33) | PTPN1CAMK2AGPR84FFAR1FFAR4 | |
| SCHEMBL3409134 | 0.93 | GPR84 (0.34) | PTPN1CAMK2AGPR84FFAR1FFAR4 | |
| SCHEMBL5942917 | 0.93 | GPR84 (0.34) | PTPN1CAMK2AGPR84FFAR1FFAR4 | |
| SCHEMBL3407667 | 0.93 | GPR84 (0.34) | PTPN1CAMK2AGPR84FFAR1FFAR4 | |
| SCHEMBL6331659 | 0.86 | THRB (0.32) | — | |
| SCHEMBL5774423 | 0.86 | THRB (0.32) | — | |
| SCHEMBL6326530 | 0.86 | THRB (0.32) | — | |
| SCHEMBL3856821 | 0.83 | CA2 (0.36) | PTPN1CAMK2APLA2G2C | |
| SCHEMBL4820666 | 0.83 | PLA2G2C (0.46) | PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4358970-A1 | COMPOUNDS FOR TREATING GENETIC DISEASES | Zikani Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-1839659-A2 | Chemicals compounds | GLAXO GROUP LIMITED (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-7226929-B2 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1395606-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LTD (GB) | 2007-05-02 | — | — | EP | disclosed |
| US-7084139-B2 | Pyrrolidin-2-one derivatives as inhibitors of factor Xa | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060160885-A1 | drugs such as 6 -Chloro-N-{(3S)-1-[(1S)-1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide, used as antithrombotic agents | GLAXO GROUP LIMITED (GB) | 2006-07-20 | — | — | US | disclosed |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2004-08-05 | — | — | US | disclosed |
| EP-1395606-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002100886-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160885-A1 | drugs such as 6 -Chloro-N-{(3S)-1-[(1S)-1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide, used as antithrombotic agents | SERPINC1, F11, TFPI | PTPN1 1229/4885CAMK2A 2804/4885GPR84 4814/4885 |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | TFPI, SERPINC1, TFPI2 | PTPN1 1165/4885CAMK2A 3531/4885GPR84 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.